Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain
Status:
Completed
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to characterize the pain control achieved with
long-term repeated dosing of OROS hydromorphone (slow release) in patients with chronic
cancer pain and the secondary purpose was to characterize the effects of pain on the
patients' quality of life with long-term, repeated dosing of OROS hydromorphone (slow
release) taken by patients with chronic cancer pain.